Search

Displaying results 1711 - 1720 of 5897 in total
  1. Drug

    Palbociclib

    go.drugbank.com/drugs/DB09073
    ApprovedInvestigational

    It is a second generation cyclin-dependent kinase inhibitor[A176798] selected from a group of pyridopyrimidine compounds due to its favorable physical and pharmaceutical properties. … [L5867] It was originally FDA approved on March 2015 for the treatment of HR-positive, HER2-negative advanced or metastatic breast cancer and its indications were updated in April 2019 to include male

    Synonyms: 6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-8h-pyrido(2,3-d)pyrimidin-7-one, 6-acetyl-8-cyclopentyl-5-methyl-2-{[5-(piperazin-1-yl)pyridin-2-yl]amino}pyrido[2,3-d]pyrimidin-7(8H)-one
  2. Drug

    Hexaminolevulinate

    go.drugbank.com/drugs/DB06261
    ApprovedInvestigational

    In solution form it is instilled intravesically for use with photodynamic blue light cystoscopy as an adjunct to white light cystoscopy. On May 28, 2010, the U.S. … use in combination with the Karl Storz Photodynamic Diagnostic D-Light C (PDD) System for cystoscopic detection of non-muscle invasive papillary cancer of the bladder for patients suspected or known to

  3. Drug

    Apremilast

    go.drugbank.com/drugs/DB05676
    ApprovedInvestigational

    It belongs to the same drug class as [Roflumilast] and [Crisaborole].[A181244,L7495] Initially approved in 2014, it is marketed by Celgene. … Apremilast, also known as Otezla, is a phosphodiesterase 4 (PDE4) inhibitor used to treat various types of symptoms resulting from certain inflammatory autoimmune diseases.

  4. Drug

    Atrasentan

    go.drugbank.com/drugs/DB06199
    ApprovedInvestigational

    In April 2025, atrasentan was granted accelerated approval by the FDA for the reduction of proteinuria in patients with primary IgA nephropathy, becoming the first endothelin A receptor antagonist to

  5. Drug

    Ambroxol

    go.drugbank.com/drugs/DB06742
    ApprovedInvestigational

    Surfactants acts as an anti-glue factor by reducing the adhesion of mucus to the bronchial wall, in improving its transport and in providing protection against infection and irritating agents.

    Products: AMBROXOLO MYLAN GENERICS
  6. Drug

    Thiotepa

    go.drugbank.com/drugs/DB04572
    ApprovedInvestigational

    It is mostly used to treat breast cancer, ovarian cancer and bladder cancer. It is also used as conditioning for Bone marrow transplantation. Its main toxicity is myelosuppression.

  7. Drug

    Xenon-133

    go.drugbank.com/drugs/DB09315
    Approved

    Xenon-133 is an inhaled radionuclide used for lung imaging, imaging blood flow in the brain, and to assess pulmonary function.

  8. Drug

    Arimoclomol

    go.drugbank.com/drugs/DB05025
    Approved

    Arimoclomol is a hydroxylamine derivative [A264414] and a heat-shock protein-70 (HSP70) co-inducer.

  9. Drug

    Plasminogen

    go.drugbank.com/drugs/DB16701
    ApprovedInvestigational

    [A236035] This pathway is activated when a clot is no longer needed or to prevent a clot from extending beyond the site of injury. … Plasminogen is a pro-enzyme (i.e. a zymogen) which is cleaved to form plasmin - also known as [fibrinolysin] - as part of the fibrinolytic pathway that breaks down fibrin blood clots.

  10. Drug

    Dimetacrine

    go.drugbank.com/drugs/DB08996
    ApprovedWithdrawn

    Dimetacrine is no longer used in Japan.

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome